Annual report: surveillance of adverse events following immunisation in Australia, 2008
DOI:
https://doi.org/10.33321/cdi.2009.33.40Keywords:
AEFI, adverse events, vaccines, surveillance, immunisation, vaccine safetyAbstract
This report summarises Australian passive surveillance data for adverse events following immunisation (AEFI) reported to the Therapeutic Goods Administration (TGA) for 2008, and describes reporting trends over the 9-year period 2000 to 2008. There were 1,542 AEFI records for vaccines administered in 2008. This was an annual AEFI reporting rate of 7.2 per 100,000 population, a 5% decrease compared with 2007. The majority of AEFI reports described non-serious events while 10% (n = 152) were classified as serious. Two deaths temporally associated with immunisation were reported; there was no evidence to suggest a causal association. The most commonly reported reactions were injection site reaction, allergic reaction, fever and headache. AEFI reporting rates in 2008 were 2.7 events per 100,000 administered doses of influenza vaccine for adults aged ≥18 years, 18.9 per 100,000 administered doses of pneumococcal polysaccharide vaccine for those aged ≥65 years, and 17.2 per 100,000 administered doses of scheduled vaccines for children aged <7 years. Reports for infants increased in 2008, mainly related to gastrointestinal system events temporally associated with receipt of rotavirus vaccine in the 1st full year of the rotavirus immunisation program, while there was a substantial decrease in AEFI reports for human papillomavirus vaccine in adolescents compared with 2007 when the program commenced. Increases in reports in children and adults were also partly attributed to the implementation of enhanced passive surveillance in Victoria. The consistently low reporting rate of serious AEFI highlights the safety of vaccines in Australia and illustrates the value of the national TGA database as a surveillance tool for monitoring AEFIs nationally. Commun Dis Intell 2009;33(4):365–381.
Downloads
References
Chen RT, DeStefano F, Pless R, Mootrey G, Kramarz P, Hibbs B. Challenges and controversies in immunization safety. Infect Dis Clin North Am 2001;15:21–39.
Duclos P. A global perspective on vaccine safety. Vaccine 2004;22:2059–2063.
Government of Western Australia. March 2008. Department of Health – Communicable Disease Control Directorate. 2009. Accessed on 2009. Available from: http://www.canningdivision.com.au/cdgp_docs/immunisation/CHANGE%20IN%20WA%20VACCINATION%20SCHEDULE%20DUE%20TO%20PEDVAX%20SHORTAGE.pdf
Immunisation Newsletter J2. 2009. Accessed on 2009. Available from: http://www.health.vic.gov.au/data/assets/pdffile/0015/130083/immunisation-newsletter-issue-32.pdf
National Immunisation Program Schedule change for Queensland March 2008. 2009. Accessed on June 2009. Available from: http://www.health.qld.gov.au/ph/Documents/cdb/imm sched gp.pdf
Quarterly newsletter produced by the Immunisation section CM2. 2008. Accessed on 2009. Available from: http://www.dh.sa.gov.au/pehs/Immunisation/0803-sharp-point-news.pdf
Centers for Disease Control and Prevention. Continued shortage of Haemophilus influenzae type b (Hib) conjugate vaccines and potential implications for Hib surveillance—United States, 2008. MMWR Morbid Mortal Wkly Rep 2008;1252–1255.
Australian Government Department of Health and Ageing. Immunisation programs and initiatives. 2007. Accessed on 1 August 2007. Available from: http://immunise.health.gov.au/internet/immunise/publishing.nsf/Content/programs
National Health and Medical Research Council. The Australian Immunisation Handbook. 8th ed. Canberra: Australian Government Department of Health and Ageing, 2003.
National Health and Medical Research Council. The Australian Immunisation Handbook. 9th ed. Canberra: Australian Government Department of Health and Ageing, 2008.
Lawrence GL, Mahajan D, Roomiani I. Supplementary report: surveillance of adverse events following immunisation among children aged less than 7 years in Australia,1 January to 30 June 2008. Commun Dis Intell 2009 2009;27–31.
Lawrence G, Menzies R, Burgess M, McIntyre P, Wood N, Boyd I, et al. Surveillance of adverse events following immunisation: Australia, 2000–2002. Commun Dis Intell 2003;27:307–323.
Lawrence G, Boyd I, McIntyre P, Isaacs D. Surveillance of adverse events following immunisation: Australia 2002 to 2003. Commun Dis Intell 2004;28:324–338.
Lawrence G, Boyd I. Surveillance of adverse events following immunisation for children aged less than 7 years, 1 January to 30 June 2004. Commun Dis Intell 2004;28:490–492.
Lawrence G, Boyd I. Supplementary report: surveillance of adverse events following immunisation among children aged less than 7 years in Australia, 1 January to 30 June 2005. Commun Dis Intell 2005;29:413–416.
Lawrence G, Boyd I, McIntyre P, Isaacs D. Annual report: surveillance of adverse events following immunisation in Australia, 2005. Commun Dis Intell 2006;30:319–333.
Lawrence G, Boyd I. Supplementary report: surveillance of adverse events following immunisation among children aged <7 years in Australia, 1 January to 30 June 2006. Commun Dis Intell 2006;30:438–442.
Lawrence G, Gold MS, Hill R, Deeks S, Glasswell A, McIntyre PB. Annual report: surveillance of adverse events following immunisation in Australia, 2007. Commun Dis Intell 2008;32:371–387.
Lawrence GL, Boyd I, McIntyre PB, Isaacs D. Annual report: surveillance of adverse events following immunisation in Australia, 2004. [erratum appears in Commun Dis Intell 2005;29(4):416]. Commun Dis Intell 2005;29:248–262.
Lawrence GL, Aratchige PE, Boyd I, McIntyre PB, Gold MS. Annual report on surveillance of adverse events following immunisation in Australia, 2006. Commun Dis Intell 2007;31:269–282.
Lawrence GL, Aratchige PE, Hill R. Supplementary report: surveillance of adverse events following immunisation among children aged less than 7 years in Australia, 1 January to 30 June 2007. Commun Dis Intell 2007;31:379–382.
Uppsala Monitoring Centre. WHO Collaborating Centre for International Drug Monitoring. WHO, 2009. Accessed on 9 February 2009. Available from: http://www.who-umc.org/
Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)—United States, 1991–2001. [erratum appears in MMWR Morb Mortal Wkly Rep. 2003 Feb 14;52(06):113]. MMWR Surveill Summ 2003;52(SS–1):1–24.
Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999;20:109–117.
Bonhoeffer J, Gold MS, Heijbel H, Vermeer P, Blumberg D, Braun M, et al. Hypotonic-hyporesponsive Episode (HHE) as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine 2004;22:563–568.
Ruggeberg JU, Gold MS, Bayas JM, Blum MD, Bonhoeffer J, Friedlander S, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007;25:5675–5684.
The SAS system for Windows [computer program]. Version 9.1.3. Cary, N.C: SAS Institute Inc, 2005.
Additional reports — Childhood immunisation coverage. Commun Dis Intell 2008;32:288–289.
Varricchio F, Iskander J, DeStefano F, Ball R, Pless R, Braun MM, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004;23:287–294.
State Government of Victoria, Department of Human Services. SAEFVIC: Surveillance of adverse events following vaccination in the community. State Government of Victoria, 2008. Accessed on 9 September 2009. Available from: http://www.health.vic.gov.au/immunisation/general/saefvic
Brotherton JM, Gold MS, Kemp AS, McIntyre PB, Burgess MA, Campbell-Lloyd S, et al. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ 2008;179:525–533.
Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007;369:1693–1702.
Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007;26:201–209.
Rennels MB, Deloria MA, Pichichero ME, Losonsky GA, Englund JA, Meade BD, et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics 2000;105:e12.
Downloads
Published
How to Cite
License
Copyright (c) 2009 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
